NeoVentures was founded in 2002 and has become the world leader in aptamer development. The company was cofounded by Ms. Ximena Vedoya and Dr. Gregory Penner based on their observation that there was a need to bridge the gap between aptamer discovery and commercial application. They have worked to improve the consistency of aptamer discovery, the reliability of binding assays, and most importantly the development of reproducible pathways to commercialization.
Both, Ms. Vedoya and Dr. Penner have strong backgrounds in the development and commercialization of technology in multinational companies. Gregory’s background in quantitative genetics, statistics and mathematics has provided a stringent commitment to understanding the principles of all phases of aptamer development and commercialization on a theoretical basis. This approach has enabled NeoVentures to develop the following industry leadership positions.
- Mathematical models of the selection process (used to guide selection project design)
- Mathematical models of commercial applications (used to define requirements)
- First to commercialize aptamer based diagnostic platforms
- Mycotoxin detection
- Prediction of baking performance of flour www.risingnumber.com
- Characterization of enrichment trajectories with Next Generation Sequencing (NGS) analysis
- Development of contrasting simultaneous selection channels to improve candidate aptamer identification
- Multiple epitope mapping for improved capture binding affinities
- Motif analysis in conjunction with structure predictions
- Rational aptamer truncation protocols
- Development of free/free selection platform to obviate need for immobilization of small molecules (FRELEX)
The team at NeoVentures continues to grow and evolve to meet the needs of our clients. Our team provides expertise in protein and peptide chemistry, molecular biology, bioinformatics, binding assay analysis, and mathematical modeling to every project we undertake. We remain committed to continuing to lead the advancement of aptamer science and to pave the way to the commercial use of aptamers in diagnostics, therapies, apheresis and consumer products.